CD8A and neoplasm: Treatment with CM from Id1Lyz-KO TAMs reduced tumor growth compared to the Id1f/f group, which was partially reversed by CD8+ T cells depletion (Fig. 3k–m), with a tumor inhibition rate ranging from ~85% (IgG treatment group) to 35% (CD8 depleting antibody group) (Fig. 3n).